The nervous system and bone.
Completed
- Conditions
- Osteoporosis
- Registration Number
- NL-OMON23544
- Lead Sponsor
- Academic Medical Center (AMC), Amsterdam
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 12
Inclusion Criteria
Age: 18-70 years.
Exclusion Criteria
1. Hypersensitivity to the active substrate or to any of the excipients;
2. Severe bradycardia, like sick sinus syndrome and a second or third degree atrioventricular block;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary objective is to study the effect of clonidine, an alpha2-adrenergic receptor agonist, on bone resorption. We will do this by comparing the change in the bone resorption marker collagen type 1 cross-linked C-telopeptide (CTX) in healthy male and female subjects who receive a single dose of clonidine and no intervention. The changes in CTX levels on the intervention day (clonidine 0.3mg) and on the control day (no intervention) will be compared.
- Secondary Outcome Measures
Name Time Method The secondary objective is to investigate the effect of clonidine on changes in catecholamine levels and the serum concentration of the bone formation marker, procollagen type I N propeptide (P1NP) on the intervention day (clonidine 0.3mg) and on the control day (no intervention).